Your inhaler’s watching you: drugmakers race for smart devices
(Reuters) – Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly.
Linked wirelessly to the cloud, the gadgets are part of a medical “Internet of Things” that promises improved adherence, or correct use of the medication, and better health outcomes. They may also hold the key to company profits in an era of increasingly tough competition.
Drugmakers believe giving patients and doctors the ability to check inhaler use in this way could be a big help in proving the value of thei...
Source: Mass Device - July 20, 2016 Category: Medical Equipment Authors: MassDevice Tags: mHealth (Mobile Health) Patient Monitoring Respiratory AstraZeneca plc GlaxoSmithKline plc Novartis AG Qualcomm Source Type: news
Strong earnings help Consort Medical recover from hit by delay in Mylan approval
Consort Medical (LON:CSRT) said the impending launch of a generic Advair inhaler by Mylan (NSDQ:MYL) represents a significant opportunity for its Bespak drug delivery device unit, but analysts were less impressed after the FDA delayed its decision date for asthma therapy to March 28, 2017.
That pushed CSRT shares down -1.9% to a $1.35 (941 pence) close yesterday on the London Stock Exchange, but investors pushed the stock up 4.9% to a $1.41 (987p) close today after Consort said it doubled the top line in fiscal 2016. Sales were up 50% to $396.4 million (£276.9 million) and pretax earnings were $46.2 million (£32....
Source: Mass Device - June 17, 2016 Category: Medical Equipment Authors: Varun Saxena Tags: Drug-Device Combinations Pharmaceuticals Respiratory Asthma Consort Medical Mylan Inc. Source Type: news
In fight for GSK's Advair, generic firms step carefully on price
LONDON (Reuters) - Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Advair Diskus (Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 23, 2016 Category: Drugs & Pharmacology Source Type: news
fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFA
Title: fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFACategory: MedicationsCreated: 1/22/2002 12:00:00 AMLast Editorial Review: 5/18/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 18, 2016 Category: Drugs & Pharmacology Source Type: news
LABA-LAMA Combo Tops Advair for Cutting COPD Flares (CME/CE)
(MedPage Today) -- Once-daily version of Utibron wins in head-to-head trial (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - May 16, 2016 Category: Geriatrics Source Type: news
Asthma Patients Treated Safely with Salmeterol-Fluticasone Combo
An FDA-mandated study finds use of LABA plus ICS in a single inhaler noninferior to ICS alone with regard to serious asthma outcomes. (Source: ConsultantLive)
Source: ConsultantLive - May 9, 2016 Category: Internal Medicine Authors: Mark L. Fuerst Tags: Asthma Source Type: news
No Greater Risk of Serious Asthma Events With Advair (CME/CE)
(MedPage Today) -- But combo treatment not necessarily safe for all asthma patients (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 7, 2016 Category: Allergy & Immunology Source Type: news
Fluticasone-Salmeterol Noninferior to Fluticasone for Serious Asthma Events (FREE)
By Kelly Young
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Fluticasone plus salmeterol is noninferior to fluticasone monotherapy in the risk for serious asthma-related events, finds an industry-conducted study in the New England Journal of … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 7, 2016 Category: Primary Care Source Type: news
AAAAI: Risks comparable in adult asthma patients given fluticasone and salmeterol plus fluticasone combo
LOS ANGELES – Fluticasone-salmeterol inhalers (Advair) are as safe as and more effective than fluticasone monotherapy inhalers are for patients with moderate to severe asthma, according to a large,... (Source: Pediatric News)
Source: Pediatric News - March 6, 2016 Category: Journals (General) Source Type: news
AAAAI: Risks comparable in adult asthma patients given fluticasone and salmeterol plus fluticasone combo
LOS ANGELES – Fluticasone-salmeterol inhalers (Advair) are as safe as and more effective than fluticasone monotherapy inhalers are for patients with moderate to severe asthma, according to a large,... (Source: Family Practice News)
Source: Family Practice News - March 6, 2016 Category: Primary Care Source Type: news
U.S. copy of GSK's Advair a step closer as Mylan files generic version
LONDON (Reuters) - The arrival of cheap generic versions of GlaxoSmithKline's top-selling lung drug Advair has moved a step closer with confirmation from Mylan that it has submitted a generic version for approval. (Source: Reuters: Health)
Source: Reuters: Health - January 12, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
New Sandoz patient-centric inhaler now available to treat adults with COPD
Novel inhaler approved for adults with chronic obstructive pulmonary disease (COPD) (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 24, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Respiratory Patient care AirFluSal copd fluticasone propionate Forspiro inhaler Latest News salmeterol Seretide Accuhaler treatment adherence Source Type: news
GSK plan to file up to 20 new drugs by 2020 underwhelms market
LONDON (Reuters) - GlaxoSmithKline could file up to 20 new drugs for regulatory approval before 2020 as it seeks to revitalize a portfolio hit by falling sales of best-selling inhaled lung treatment Advair, the company said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - November 3, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Advair revenue down again, but GSK looks to next-gen (and Zebulon) for replacement revenue
London-based GlaxoSmithKline (NYSE: GSK) reported quarterly earnings good enough for investors to trade the stock up more than 2 percent Wednesday. In the Triangle, however, those with a keen eye on the drug giant looked more closely at Advair, which again reported declining revenue.
For the first half of 2015, GSK reported $1.37 billion in U.S. sales for Advair, an asthma drug, a figure down 19 percent from last year. The Triangle focuses on Advair because GSK leans heavily on its plant in Zebulon… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 29, 2015 Category: Biotechnology Authors: Jason deBruyn Source Type: news
